Cholerose 20mg Rosuvastatin
Description
BRAND NAME: Cholerose 20mg
ABOUT THE PRODUCT: Cholerose 20mg is a powerful solution designed to support your cardiovascular health by effectively managing cholesterol levels. By combining the potent properties of Rosuvastatin and Ezetimibe, this medication helps your body lower harmful "bad" cholesterol (LDL) while simultaneously boosting levels of beneficial "good" cholesterol (HDL). Incorporating this into your physician-prescribed routine helps you maintain a healthier lipid profile, which is a vital step in protecting your heart and supporting long-term well-being.
BENEFITS & KEY FEATURES:
- Heart Health Support: Effectively lowers LDL cholesterol and triglycerides while increasing HDL, helping to maintain healthy blood lipid levels.
- Versatile Treatment: A trusted choice for managing both standard high cholesterol and specific hereditary forms of the condition.
- Dual-Action Formula: Contains a specialized combination of Rosuvastatin and Ezetimibe to ensure comprehensive lipid management as directed by your doctor.
HOW TO USE SAFELY:
- Directions: This medication must be taken strictly as prescribed by your physician. Dosage and frequency are tailored to your specific medical profile, age, and individual response to treatment. Please follow your doctor's instructions exactly regarding the daily intake of your tablets.
- Important Tips: Regular monitoring of your lipid levels is essential as directed by your healthcare provider. Avoid consumption of grapefruit or excessive alcohol, and ensure your doctor is aware of any other medications or supplements you are currently taking, especially if you have existing kidney or liver conditions.
SAFETY NOTE: Please consult your healthcare professional or physician before use. Not intended for use by individuals with active liver disease or those with known hypersensitivity to the ingredients. Discontinue use and seek medical advice immediately if you experience unexplained muscle pain, weakness, or symptoms of liver dysfunction.

